These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16533866)

  • 1. Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys.
    Madsen MV; Peacock L; Werge T; Andersen MB
    J Psychopharmacol; 2006 Sep; 20(5):622-8. PubMed ID: 16533866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cannabinoid CB1 receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys.
    Madsen MV; Peacock LP; Werge T; Andersen MB; Andreasen JT
    Neuropharmacology; 2011; 60(2-3):418-22. PubMed ID: 21029743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats.
    Seillier A; Advani T; Cassano T; Hensler JG; Giuffrida A
    Int J Neuropsychopharmacol; 2010 Apr; 13(3):373-86. PubMed ID: 19607756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat.
    Martin RS; Secchi RL; Sung E; Lemaire M; Bonhaus DW; Hedley LR; Lowe DA
    Psychopharmacology (Berl); 2003 Jan; 165(2):128-35. PubMed ID: 12404071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys.
    Andersen MB; Fuxe K; Werge T; Gerlach J
    Behav Pharmacol; 2002 Dec; 13(8):639-44. PubMed ID: 12478214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the cannabinoid receptor ligands on anxiety-related effects of d-amphetamine and nicotine in the mouse elevated plus maze test.
    Biala G; Kruk M; Budzynska B
    J Physiol Pharmacol; 2009 Jun; 60(2):113-22. PubMed ID: 19617654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of active and inactive states of CB1 receptor and the differential binding state modulation by cannabinoid agonists, antagonists and inverse agonists.
    Gullapalli S; Amrutkar D; Gupta S; Kandadi MR; Kumar H; Gandhi M; Karande V; Narayanan S
    Neuropharmacology; 2010 Jun; 58(8):1215-9. PubMed ID: 20214912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute D-amphetamine.
    Polissidis A; Chouliara O; Galanopoulos A; Naxakis G; Papahatjis D; Papadopoulou-Daifoti Z; Antoniou K
    Behav Brain Res; 2014 Aug; 270():261-9. PubMed ID: 24867330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat.
    Scott DA; Wright CE; Angus JA
    Pain; 2004 May; 109(1-2):124-31. PubMed ID: 15082134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The substituted (S)-3-phenylpiperidine (-)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys.
    Brandt-Christensen M; Andersen MB; Fink-Jensen A; Werge T; Gerlach J
    J Neural Transm (Vienna); 2006 Jan; 113(1):11-9. PubMed ID: 15795789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice.
    Grim TW; Wiebelhaus JM; Morales AJ; Negus SS; Lichtman AH
    Drug Alcohol Depend; 2015 May; 150():31-7. PubMed ID: 25772438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine.
    Guidali C; Viganò D; Petrosino S; Zamberletti E; Realini N; Binelli G; Rubino T; Di Marzo V; Parolaro D
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):17-28. PubMed ID: 20196921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of cannabinoid CB1 receptor agonist and antagonist on timing impulsivity induced by d-amphetamine in a differential reinforcement of low-rate response task in male rats.
    Chen SF; Hsu WC; Lu XY; Chuang CY; Liao RM
    Psychopharmacology (Berl); 2022 May; 239(5):1459-1473. PubMed ID: 34741633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21.
    Pavon FJ; Bilbao A; Hernández-Folgado L; Cippitelli A; Jagerovic N; Abellán G; Rodríguez-Franco MA; Serrano A; Macias M; Gómez R; Navarro M; Goya P; Rodríguez de Fonseca F
    Neuropharmacology; 2006 Aug; 51(2):358-66. PubMed ID: 16750544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys.
    Andersen MB; Werge T; Fink-Jensen A
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1179-82. PubMed ID: 17374745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats.
    Cippitelli A; Bilbao A; Hansson AC; del Arco I; Sommer W; Heilig M; Massi M; Bermúdez-Silva FJ; Navarro M; Ciccocioppo R; de Fonseca FR;
    Eur J Neurosci; 2005 Apr; 21(8):2243-51. PubMed ID: 15869521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core.
    Schoffelmeer AN; Hogenboom F; Wardeh G; De Vries TJ
    Neuropharmacology; 2006 Sep; 51(4):773-81. PubMed ID: 16806307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates.
    Foltin RW; Haney M
    Pharmacol Biochem Behav; 2007 Apr; 86(4):766-73. PubMed ID: 17445873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analogs of SR-141716A (Rimonabant) alter d-amphetamine-evoked [3H] dopamine overflow from preloaded striatal slices and amphetamine-induced hyperactivity.
    Miller DK; Rodvelt KR; Constales C; Putnam WC
    Life Sci; 2007 Jun; 81(1):63-71. PubMed ID: 17532007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
    Welch SP; Huffman JW; Lowe J
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.